BrightSpring Health Services (BTSG) investor relations material

Growth performance and drivers

• Achieved 20% top-line and 25%-30% EBITDA growth in recent years, surpassing historical mid-teens targets.

• Growth driven by scale, operational initiatives, and M&A platform across pharmacy and provider businesses.

• Specialty pharmacy outperformed company average, supported by high-quality services and consistent LDD wins.

• Lean Six Sigma processes embedded to drive operational efficiency and formalize growth initiatives.

• LDD wins from 2024 underpin revenue growth through 2026, with oncology and rare/orphan drugs as key focus areas.

Forward outlook and strategic initiatives

• Projecting 15%-20% growth from 2026-2028, underpinned by strong volume growth and market expansion.

• LDD pipeline visibility extends 12-18 months ahead, supporting confidence in future growth.

• Home infusion targeted for expansion in 5-10 new markets, with both organic and M&A strategies considered.

• Provider business focuses on home health, hospice, and primary care, leveraging pharmacy network for integrated care.

• Strategic growth includes unlocking referral and integrated care opportunities, plus highly accretive M&A.

Integrated business model and value creation

• One company model serves patients with multiple chronic conditions across pharmacy and provider services.

• Coordinated care leads to improved outcomes, including a 72% reduction in hospitalizations for patients receiving both home health and pharmacy services.

• Enhanced rate contracts secured for quality outcomes, especially in home health, supporting value-based care.

• Scale enables investment in targeted growth areas and best practice deployment across business lines.

• Integration of services and best practices across nursing, IT, and finance supports continued growth.